CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

Trimetazidine

For more information on our products custom synthesis, contact SynZeal today.

standards@synzeal.com www.synzeal.com

SZ-T036001

Trimetazidine DiHCl

13171-25-0

C14H22N2O3.2HCl

266.34 2 36.46

SZ-T036002

Trimetazidine EP Impurity A

52146-35-7

C14H22N2O3

266.34

SZ-T036003

Trimetazidine EP Impurity B

1257-19-8

C24H34N2O6

446.55

SZ-T036004

Trimetazidine EP Impurity C

2103-57-3

C10H12O4

196.2

SZ-T036005

Trimetazidine EP Impurity D

71989-96-3

C10H14O4

198.22

SZ-T036006

Trimetazidine EP Impurity E

356083-64-2 (free base)

C14H22N2O3.2HCl

266.34 2 36.46

SZ-T036007

Trimetazidine EP Impurity F

113698-83-2

C14H22N2O3.2HCl

266.34 2 36.46

SZ-T036008

Trimetazidine EP Impurity G

110-85-0

C4H10N2

86.14

SZ-T036009

Trimetazidine EP Impurity H

53531-01-4

C17H26N2O5

338.41

SZ-T036010

Trimetazidine EP Impurity I

53960-20-6

C15H24N2O3.2HCl

280.37 2 36.46

SZ-T036011

Trimetazidine EP Impurity J

879646-17-0

C15H22N2O4.HCl

294.35 36.46

SZ-T036012

Trimetazidine N-Oxide

N/A

C14H22N2O4

282.34

SynZeal Research offers all related impurities which certified COA with all characterization data like IR, Mass, HPLC Trimetazidinepurity,NMR & TGA report. We also provide CMR, DEPT and detailed structurecharacterization report as perrequirements.

related products are being used by major pharmaceutical companies across the globe for their ANDA/DMF filing.Trimetazidine

Trimetazidine is a drug for angina pectoris sold under the brand name Vastarel MR. Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity, which results in a reduction in fatty acid oxidation and a stimulation of glucose oxidation. High fatty acid oxidation rates are detrimental during ischemia due to an inhibition of glucose oxidation leading to uncoupling of glycolysis and an increase in proton production, which has the potential to accelerate sodium and calcium overload in the heart, which leads to an exacerbation of ischemic injury and decreased cardiac efficiency during reperfusion.